Molecular and clinical characteristics of MSH6 germline variants detected in colorectal cancer patients

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2909-2916

  Terui, Hiroko ^a,b   Tachikawa, Tetsuhiko ^a   Kakuta, Miho ^a   Nishimura, Yoji ^a   Yatsuoka, Toshimasa ^a   Yamaguchi, Kensei ^a   Yura, Kei ^b   Akagi, Kiwamu ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b OCHANOMIZU UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Endometrial cancer; HNPCC; Immunohistochemistry; Lynch syndrome; Microsatellite instability; MSH6

Indexed keywords

PROTEIN MSH6;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENDOMETRIUM CANCER; FEMALE; GENETIC VARIABILITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPANESE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR DYNAMICS; MSH6 GENE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS;

EID: 84892379916     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2781     Document Type: Article

References (38)

1. Lynch HT and de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 348: 919-932, 2003.
2. Grover S and Syngal S: Genetic testing in gastroenterology: Lynch syndrome. Best Pract Res Clin Gastroenterol 23: 185-196, 2009.
3. Hampel H, Frankel WL, Martin E, et al: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26: 5783-5788, 2008.
4. Aaltonen LA, Salovaara R, Kristo P, et al: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338: 1481-1487, 1998.
5. Wijnen J, de Leeuw W, Vasen H, et al: Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 23: 142-144, 1999.
6. Vasen HF, Mecklin JP, Khan PM and Lynch HT: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34: 424-425, 1991.
7. Baglietto L, Lindor NM, Dowty JG, et al: Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 102: 193-201, 2010.
8. Berends MJW, Wu Y, Sijmons RH, et al: Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 70: 26-37, 2002.
9. Hendriks YMC, Wagner A, Morreau H, et al: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127: 17-25, 2004.
10. Wijnen JT, Vasen HF, Khan PM, et al: Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 339: 511-518, 1998.
11. Cunningham JM, Christensen ER, Tester DJ, et al: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58: 3455-3460, 1998.
12. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870-6875, 1998.
13. Kane MF, Loda M, Gaida GM, et al: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57: 808-811, 1997.
14. Bessa X, Ballesté B, Andreu M, et al: A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 6: 206-214, 2008.
15. Akagi K, Uchibori R, Yamaguchi K, Kurosawa K, Tanaka Y and Kozu T: Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem Biophys Res Commun 352: 728-732, 2007.
16. Vasen HF, Watson P, Mecklin JP and Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116: 1453-1456, 1999.
17. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268, 2004.
18. Ohsawa T, Sahara T, Muramatsu S, et al: Colorectal cancer susceptibility associated with the hMLH1 V384D variant. Mol Med Rep 2: 887-891, 2009.
19. Asaka S, Arai Y, Nishimura Y, et al: Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Carcinogenesis 30: 494-499, 2009.
20. Campbell PT, Curtin K, Ulrich CM, et al: Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut 58: 661-667, 2009.
21. Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50: 113-130, 2007.
22. Terui H, Akagi K, Kawame H and Yura K: CoDP: predicting the impact of unclassified genetic variants in MSH6 by the combination of different properties of the protein. J Biomed Sci 20: 25, 2013.
23. Ng PC and Henikoff S: Predicting deleterious amino acid substitutions. Genome Res 11: 863-874, 2001.
24. Adzhubei IA, Schmidt S, Peshkin L, et al: A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249, 2010.
25. Ali H, Olatubosun A and Vihinen M: Classification of mismatch repair gene missense variants with PON-MMR. Hum Mutat 33: 642-650, 2012.
26. Woods MO, Williams P, Careen A, Edwards L, Bartlett S, McLaughlin JR and Younghusband HB: A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 28: 669-673, 2007.
27. Stenson PD, Ball E V, Mort M, Phillips AD, Shaw K and Cooper DN: The Human Gene Mutation Database (HGMD) and its exploitation in the fields of personalized genomics and molecular evolution. Curr Protoc Bioinformatics 39: 1.13, 2012.
28. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM and Sirotkin K: dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311, 2001.
29. Engel C, Loeffler M, Steinke V, et al: Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 30: 4409-4415, 2012.
30. Peltomäki P: Lynch syndrome genes. Fam Cancer 4: 227-232, 2005.
31. Vasen HFA: Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment Pharmacol Ther 26: 113-126, 2007.
32. Zhao Y, Hu F, Wang F, Han B, Li D, Li X and Zhu S: Meta-analysis of MSH6 gene mutation frequency in colorectal and endometrial cancers. J Toxicol Environ Health A 72: 690-697, 2009.
33. Okkels H, Lindorff-Larsen K, Thorlasius-Ussing O, et al: MSH6 mutations are frequent in hereditary nonpolyposis colorectal cancer families with normal pMSH6 expression as detected by immunohistochemistry. Appl Immunohistochem Mol Morphol 20: 470-477, 2012.
34. Plon SE, Eccles DM, Easton D, et al: Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29: 1282-1291, 2008.
35. Ellison AR, Lofing J and Bitter GA: Functional analysis of human MLH1 and MSH2 missense variants and hybrid human-yeast MLH1 proteins in Saccharomyces cerevisiae. Hum Mol Genet 10: 1889-1900, 2001.
36. Gammie AE, Erdeniz N, Beaver J, Devlin B, Nanji A and Rose MD: Functional characterization of pathogenic human MSH2 missense mutations in Saccharomyces cerevisiae. Genetics 177: 707-721, 2007.
37. Polaczek P, Putzke AP, Leong K and Bitter GA: Functional genetic tests of DNA mismatch repair protein activity in Saccharomyces cerevisiae. Gene 213: 159-167, 1998.
38. Furihata M, Shuin T, Takeuchi T, Sonobe H, Ohtsuki Y, Akiyama Y and Yuasa Y: Missense mutation of the hMSH6 and p53 genes in sporadic urothelial transitional cell carcinoma. Int J Oncol 16: 491-496, 2000.